Please login to the form below

Not currently logged in

Amra appoints new VP of North American sales Jeremy Edwards

Klas Themner and Simon Hager also join its Sweden base

Jeremy EdwardsBody composition analysis group, Amra, has made a trio of new-hires to support its growth and expansion of its operations into the US.

Jeremy Edwards (pictured right) joins the group as its new vice president of Sales, North America, a role that will see him direct overall sales and operations growth, focusing on expanding Amra’s relationships in the pharmaceutical and biotech industry.

With more than 20 years’ experience in the clinical development industry, Edwards joins the company after spending five years as vice president and general manager of the US operations for Exco InTouch, a digital healthcare and patient engagement organisation.

He said: “I am excited to join Amra at this pivotal time in its growth.

Klas Themner“The company is advancing the understanding of metabolic status across a multitude of diseases and I look forward to working with our talented team, as well as our customers, as we expand the US market.”

Meanwhile, Klas Themner (pictured left) joins its Sweden base as senior vice president, product development from Exini Diagnostics and he has 20 years’ experience in operations development.

Simon HagerSimon Hager (pictured right) also joins the office as its European Sales Manager after leading the global digital pathology offering at Sectra.

Tommy Johansson, chief executive officer, Amra, said: “We are confident that with a permanent base in the US, the support of our new VP of sales, and with two strong additions to our Swedish team, we will continue to grow.”

9th October 2017

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge